Tarsus Pharmaceuticals, Inc. — Director's Dealing 2021

Sep 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2021-09-10

Reporting Person: Mottiwala Aziz (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-10	Common Stock	M	4350	$10.99	Acquired	58203	Direct
2021-09-10	Common Stock	M	2593	$0.45	Acquired	60796	Direct
2021-09-10	Common Stock	S	2593	$22.15	Disposed	58203	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-10	Employee Stock Option (right to buy)	$10.99	M	4350	Disposed	2030-09-24	Common Stock (4350.0)	Direct
2021-09-10	Employee Stock Option (right to buy)	$0.45	M	2593	Disposed	2028-09-13	Common Stock (2593.0)	Direct

Footnotes

F1: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $22.000 to $22.200. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020.

F3: Option granted under the Plan. 25% of the option shares vested and became exercisable on July 27, 2019 and the remaining option shares vest and become exercisable in 36 equal monthly installments thereafter.